I have previously written about whether thrombosis (formation of blood clots) is linked to the AstraZeneca COVID-19 vaccine – my conclusion was that they probably weren’t. But still, there are nagging anecdotes and government decisions that may concern those of you who are looking to get the vaccine.
Recently, the government of Quebec recently decided that the AstraZeneca vaccine will only be used on individuals 55 years and older. Of course, this caused some parts of the anti-vaccine world to froth at the mouth claiming the vaccine isn’t safe.
I think that many of the adverse events that are claimed to be associated with any of the COVID-19 vaccines involve the post hoc ergo propter hoc fallacy, which states that because one event precedes another event, they must be linked. It is entirely possible that thrombosis occurs after vaccinations because of random chance rather than actual correlation (let alone causation).
Because the AstraZeneca COVID-19 vaccine is one of the four main vaccines (along with those from Pfizer, Moderna, and JNJ) to be given in the USA, Canada, the EU, Australia, and New Zealand, I want to make sure that the potential of a causal link to thrombosis events are given a thorough analysis. I especially want to focus on why the Government of Quebec decided to make this change – and it’s a lot more complicated than the narratives pushed by the anti-vaccine crowd.
Here we go again. We recently wrote about Diane Harper, another “lead developer” of the HPV vaccines, who has a rather complicated view on HPV vaccines. She makes disparaging remarks about the vaccine, yet her peer reviewed publications are generally favorable to the HPV vaccine. Genevieve Rail, a kinesiology researcher at Concordia University in Montreal, Quebec, Canada is the next one being pushed by anti-vaccine activists.
Outrageous claims are made about Genevieve Rail’s expertise with HPV vaccines, like Gardasil. And she helps with the claims by making outlandish comments about the vaccine:
“I’m sort of raising a red flag, out of respect for what I’ve found in my own study, and for the despair of parents who had totally perfect 12-year-olds who are now in their beds, too tired to go to school. Yes, we’re going against the grain, and we are going against those who are believed, i.e. doctors and nurses and people in public health.”
A new research study published in Clinical Infectious Diseases has demonstrated that the MMR vaccine (measles, mumps and rubella) was more effective in teenagers who received their first dose of the two dose series at 15 months rather than at 12 months. The study was based on a more than 750 cases in 2011 of measles were reported in Quebec, Canada. Those individuals had received the routine 2-dose measles immunization schedule which is given at 12 and 18 months of age, which had been in effect in Quebec since 1996. This study assessed the effectiveness of this schedule during this outbreak that occurred during high school. Continue reading “Measles vaccine may be more effective if administered slightly later”